Nothing Special   »   [go: up one dir, main page]

ATE452880T1 - 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren - Google Patents

2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren

Info

Publication number
ATE452880T1
ATE452880T1 AT01946854T AT01946854T ATE452880T1 AT E452880 T1 ATE452880 T1 AT E452880T1 AT 01946854 T AT01946854 T AT 01946854T AT 01946854 T AT01946854 T AT 01946854T AT E452880 T1 ATE452880 T1 AT E452880T1
Authority
AT
Austria
Prior art keywords
group
mono
tyrosine kinase
receptor tyrosine
independently
Prior art date
Application number
AT01946854T
Other languages
English (en)
Inventor
Paul Manley
Guido Bold
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE452880T1 publication Critical patent/ATE452880T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01946854T 2000-01-27 2001-01-25 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren ATE452880T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001930.7A GB0001930D0 (en) 2000-01-27 2000-01-27 Organic compounds
PCT/EP2001/000835 WO2001055114A1 (en) 2000-01-27 2001-01-25 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE452880T1 true ATE452880T1 (de) 2010-01-15

Family

ID=9884488

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01946854T ATE452880T1 (de) 2000-01-27 2001-01-25 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren

Country Status (25)

Country Link
US (1) US6624174B2 (de)
EP (2) EP2168948B1 (de)
JP (1) JP3894793B2 (de)
KR (1) KR100554988B1 (de)
CN (1) CN1216867C (de)
AT (1) ATE452880T1 (de)
AU (1) AU771626B2 (de)
BR (1) BR0107805A (de)
CA (1) CA2396590C (de)
CZ (1) CZ20022582A3 (de)
DE (1) DE60140860D1 (de)
ES (2) ES2490191T3 (de)
GB (1) GB0001930D0 (de)
HK (1) HK1050895A1 (de)
HU (1) HUP0204083A3 (de)
IL (2) IL150481A0 (de)
MX (1) MXPA02007319A (de)
NO (1) NO323826B1 (de)
NZ (1) NZ520005A (de)
PL (1) PL356307A1 (de)
PT (2) PT1259487E (de)
RU (1) RU2296124C2 (de)
SK (1) SK287426B6 (de)
WO (1) WO2001055114A1 (de)
ZA (1) ZA200205988B (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
US7419428B2 (en) * 2000-04-28 2008-09-02 Igt Cashless transaction clearinghouse
DE10023492A1 (de) * 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
BRPI0113757B1 (pt) 2000-09-11 2017-05-23 Chiron Corp derivados de quinolinona como inibibores de tirosina quinase
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1392680B1 (de) * 2001-05-08 2009-07-22 Bayer Schering Pharma Aktiengesellschaft Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
CA2493026C (en) * 2002-07-31 2011-05-24 Schering Aktiengesellschaft Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
EP2573079A3 (de) 2002-08-23 2015-03-11 Novartis AG Benzimidazolchinolinonderivate und ihre Verwendung
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
ES2441176T3 (es) 2003-03-07 2014-02-03 Santen Pharmaceutical Co., Ltd. Nuevo compuesto que tiene un grupo 4-piridilalquiltio como sustituyente
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
WO2005027973A2 (en) * 2003-09-23 2005-03-31 Novartis Ag Combinations of a vegf receptor inhibitor with other therapeutic agents
EA200600495A1 (ru) * 2003-09-23 2006-10-27 Новартис Аг Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
KR20060111520A (ko) 2003-11-07 2006-10-27 카이론 코포레이션 Ｆｇｆｒ3의 억제 및 다발성 골수종의 치료
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
US7544703B2 (en) 2004-02-17 2009-06-09 Santen Pharmaceutical Co., Ltd. Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
EP1657241A1 (de) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Neue Antranilamidpyrdinharnstoffe mit hemmender Wirkung auf VEGF-Rezeptor Kinase
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655295A1 (de) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamid-Pyridinharnstoffe als VEGF Rezeptor Kinase Inhibitoren
JPWO2006070878A1 (ja) * 2004-12-28 2008-06-12 アステラス製薬株式会社 カルボン酸誘導体またはその塩
US8597947B2 (en) 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
WO2006070370A2 (en) 2004-12-29 2006-07-06 Hadasit Medical Research Services & Development Limited Stem cells culture systems
ES2351613T3 (es) * 2005-03-03 2011-02-08 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que tiene un grupo quinolilalquiltio.
EP1864977B1 (de) 2005-03-31 2015-07-29 Santen Pharmaceutical Co., Ltd. Neue cyclische verbindung mit pyrimidylalkylthiogruppe
PL1888556T3 (pl) 2005-05-17 2012-03-30 Novartis Ag Metody syntetyzowania związków heterocyklicznych
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
AU2006320591B2 (en) 2005-11-29 2010-06-03 Novartis Ag Formulations of quinolinones
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
KR101475540B1 (ko) 2007-01-29 2014-12-22 산텐 세이야꾸 가부시키가이샤 혈관 신생 저해 활성을 갖는 신규 옥사디아졸 유도체 및 티아디아졸 유도체
ES2527444T5 (es) 2007-04-18 2018-05-17 Hadasit Medical Research Services & Development Limited Células del epitelio pigmentario de la retina derivadas de células madre
EP2238448B1 (de) * 2008-01-07 2016-04-06 Ortho-Clinical Diagnostics, Inc. Kalibrator/steuerung für simultanen test von untereinander komplexierungsfähigen proteinen
MX2010010505A (es) * 2008-03-26 2010-10-26 Novartis Ag Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
CN102131782B (zh) * 2008-08-27 2014-07-30 利奥制药有限公司 作为vegf-2受体和蛋白酪氨酸激酶抑制剂的吡啶衍生物
CN101676267B (zh) * 2008-09-16 2012-12-26 江苏恒瑞医药股份有限公司 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
AU2010294209A1 (en) 2009-09-10 2012-03-29 Irm Llc Ether derivatives of bicyclic heteroaryls
CN102665718B (zh) 2009-10-06 2016-03-09 米伦纽姆医药公司 可用作pdk1抑制剂的杂环化合物
WO2011064211A1 (en) 2009-11-25 2011-06-03 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
US20130090342A1 (en) 2010-06-17 2013-04-11 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CN103492390A (zh) 2011-03-08 2014-01-01 诺瓦提斯公司 氟苯基双环杂芳基化合物
KR101412794B1 (ko) * 2011-07-27 2014-07-01 보령제약 주식회사 혈관생성억제 작용을 갖는 신규한 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
EA201491857A1 (ru) * 2012-05-08 2015-04-30 АНВИЛ ЭлЭлСи АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ α7 НИКОТИНОВОГО ХОЛИНОРЕЦЕПТОРА, ИХ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ
RU2718054C2 (ru) * 2013-11-28 2020-03-30 СиЭсЭл ЛИМИТЕД Способ лечения нефропатии
CN114634483B (zh) * 2014-02-21 2024-08-13 弗洛斯特生物科技有限公司 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺
EP3240890B1 (de) 2014-12-30 2021-06-16 Cell Cure Neurosciences Ltd. Beurteilung von netzhautpigmentepithelzellpopulationen
WO2016108239A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Rpe cell populations and methods of generating same
JP7055095B2 (ja) 2015-07-29 2022-04-15 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 網膜色素上皮細胞の大規模生産
CN108138145A (zh) 2015-08-05 2018-06-08 细胞治疗神经科学有限公司 用于治疗视网膜疾病的光感受器的制备
EA201890424A1 (ru) 2015-08-05 2018-06-29 Селл Кьюр Нейросайансес Лтд. Получение клеток пигментного эпителия сетчатки
CA2995675C (en) 2015-08-31 2023-12-12 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as therapeutic drugs
CA3002919A1 (en) 2015-10-26 2017-05-04 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
BR112019019190A2 (pt) 2017-03-16 2020-04-22 Lineage Cell Therapeutics Inc métodos para o tratamento de doenças da retina
EP3697425A1 (de) 2017-10-18 2020-08-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Verfahren und verbindungen zur verbesserten immunzelltherapie
AU2017444054B2 (en) 2017-12-21 2021-10-07 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Class of pyrimidine derivative kinase inhibitors
CN113038951B (zh) 2018-09-20 2024-04-30 耶达研究及发展有限公司 治疗肌萎缩侧索硬化的方法
EP3754014A1 (de) 2019-06-21 2020-12-23 Centre d'Etude des Cellules Souches (CECS) Automatisiertes verfahren zur herstellung von retinalen pigmentepithelzellen
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
WO2022261320A1 (en) 2021-06-09 2022-12-15 Lineage Cell Therapeutics, Inc. Methods and compositions for treating retinal diseases and conditions
JP2024527986A (ja) 2021-07-28 2024-07-26 リネージ セル セラピューティクス インコーポレイテッド 網膜色素上皮細胞の増殖
WO2023211857A1 (en) 2022-04-25 2023-11-02 Lineage Cell Therapeutics, Inc. Methods and compositions for treating vision loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0393529T3 (da) 1989-04-20 1993-11-15 Boehringer Ingelheim Pharma 5,11-Dihydro-6H-dipyrido(3,2-b:2,3-e)(1,4)diazepin-6-oner og deres anvendelse ved forhindring eller behandling af AIDS
AU720429B2 (en) * 1996-08-23 2000-06-01 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
EP0971894A1 (de) 1997-04-04 2000-01-19 Pfizer Products Inc. Nicotinamid-derivate
WO1998057957A1 (fr) 1997-06-18 1998-12-23 Nissan Chemical Industries, Ltd. Composes pyridiniques et herbicides associes
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
JP2002516909A (ja) * 1998-06-05 2002-06-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換１−（４−アミノフェニル）ピラゾール及び抗炎症剤としてのそれらの使用
AU2054700A (en) 1998-12-23 2000-07-31 Eli Lilly And Company Antithrombotic amides
DK1169038T3 (da) * 1999-04-15 2012-11-26 Bristol Myers Squibb Co Cykliske proteintyrosinkinaseinhibitorer
JP2003520854A (ja) 2000-01-27 2003-07-08 サイトビア インコーポレイテッド カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用

Also Published As

Publication number Publication date
JP2003520853A (ja) 2003-07-08
SK10852002A3 (sk) 2003-05-02
NO323826B1 (no) 2007-07-09
NO20023218D0 (no) 2002-07-02
ES2490191T3 (es) 2014-09-03
PT2168948E (pt) 2014-08-26
GB0001930D0 (en) 2000-03-22
EP2168948B1 (de) 2014-05-07
EP1259487B1 (de) 2009-12-23
RU2296124C2 (ru) 2007-03-27
EP1259487A1 (de) 2002-11-27
PL356307A1 (en) 2004-06-28
NZ520005A (en) 2004-02-27
SK287426B6 (sk) 2010-09-07
HK1050895A1 (en) 2003-07-11
HUP0204083A3 (en) 2005-03-29
AU771626B2 (en) 2004-04-01
IL150481A (en) 2009-09-22
ZA200205988B (en) 2003-07-28
CZ20022582A3 (cs) 2002-10-16
HUP0204083A2 (hu) 2003-03-28
KR100554988B1 (ko) 2006-02-24
CA2396590A1 (en) 2001-08-02
AU2849901A (en) 2001-08-07
US6624174B2 (en) 2003-09-23
CA2396590C (en) 2011-03-01
KR20020071973A (ko) 2002-09-13
NO20023218L (no) 2002-09-16
EP2168948A1 (de) 2010-03-31
DE60140860D1 (de) 2010-02-04
US20030032656A1 (en) 2003-02-13
WO2001055114A1 (en) 2001-08-02
JP3894793B2 (ja) 2007-03-22
ES2338407T3 (es) 2010-05-07
EP1259487B8 (de) 2014-04-23
BR0107805A (pt) 2002-10-22
IL150481A0 (en) 2002-12-01
CN1216867C (zh) 2005-08-31
CN1396912A (zh) 2003-02-12
PT1259487E (pt) 2010-03-26
MXPA02007319A (es) 2002-11-29

Similar Documents

Publication Publication Date Title
DE60140860D1 (de) 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren
ATE180468T1 (de) Anthranilsäure derivate
MX2007006821A (es) Derivados de 2,4 (4,6) pirimidina.
DE69428476D1 (de) Heterocyclische Verbindungen als Bradykinin Antagonisten
DE69614147D1 (de) Chinazolin-derivate
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
ATE496035T1 (de) Stickstoffenthaltende heterocyclische verbindungen
ATE274512T1 (de) Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten
MXPA01004256A (es) N-arilamidas del acido antranilico y del acido tioantranilico.
EP1396493A4 (de) Heterocyclische verbindungen
EA200601235A1 (ru) Производные тиазола
DE60115465D1 (de) Immunoregulierende verbindungen, deren derivate und ihre verwendung
DE3781080D1 (de) 2-substituierte-e-kondensierte(1,2,4)triazolo-(1,5-c)pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
ATE324890T1 (de) Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
TR200103789T2 (tr) Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller.
PT1315730E (pt) Derivados de 1-[alquil],1-[(heteroaril)-alquil] e 1-[(aril)-alquil]-7-piridinil-imidazo[1,2-a]pirimidin-5(1h)-ona
DK0780125T3 (da) Anvendelse af hydantoinderivater til fremstilling af et lægemiddel til behandling af sygdomme associeret med tilstedeværelse af aktivt oxygen og frie radikaler
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
DE69720966D1 (de) Benzo[c]chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
EA199800720A1 (ru) Гетероциклические производные эрголина в качестве лигандов 5-htia рецептора
CA2385244A1 (en) Novel nicotinonitrile compounds
TH73281A (th) อนุพันธ์แอริลแอโซล, การผลิตสารเหล่านั้นและการใช้เป็นเอเจนท์บำบัด

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1259487

Country of ref document: EP